EVOQ Therapeutics Inc., a biotechnology company developing therapies for autoimmune diseases, has entered into a collaboration and license agreement with Sanofi, a global biopharmaceutical company focused on R&D and artificial intelligence-driven innovation.

The partnership centers on EVOQ’s proprietary NanoDisc technology, which is designed to restore immune tolerance—a key mechanism that fails in autoimmune diseases such as celiac disease, type 1 diabetes, MOG antibody disease, rheumatoid arthritis, and lupus. According to EVOQ, current treatments do not address the underlying cause of autoimmune conditions, which involves the immune system mistakenly attacking the body’s own tissues.

“We are truly thrilled to be collaborating with Sanofi to advance our NanoDisc technology,” said David Giljohann, Ph.D., CEO at EVOQ. Giljohann added, “Sanofi’s know-how in autoimmune disease and leadership in immunology will bring clinical development expertise and commercial presence thereby making Sanofi a highly credible and attractive partner for our technology, uniquely positioned to deliver breakthrough efficacy and convenience for patients.”

Under the terms of the agreement, EVOQ and Sanofi will jointly conduct research activities, with Sanofi assuming responsibility for global development and commercialization. EVOQ is eligible to receive over $500 million in upfront, preclinical, development, and sales milestone payments, in addition to tiered royalties on future product sales.

The specific goals and scope of the collaboration have not been publicly disclosed.